121.42 +0.04 (0.03%)
After hours: 4:00PM EDT
|Bid||121.36 x 400|
|Ask||121.42 x 100|
|Day's Range||120.72 - 121.77|
|52 Week Range||112.39 - 131.56|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||0.20%|
If you’re a fan of active management, there’s ample reason to like the Fidelity Total Bond mutual fund. It’s Gold-rated by Morningstar and has beaten the Bloomberg Barclays US Aggregate Bond Index by one percentage point annually over the past 10 years. At Charles Schwab, for instance, buying the Fidelity mutual fund (FTBFX), which isn’t on Schwab’s no-transaction-fee OneSource platform, costs $76.
For many, passive indexing against a robust U.S. index is a sound strategy. But academic research suggests there may be a view ways to improve risk-adjusted returns beyond this. We explore implementing these strategies with popular ETFs.
The excitement surrounding the tournament and its impact on the stock world has led investors to look at ETFs that could act as a proxy for the game.
Waiting for a bear market may seem like waiting for Godot—it’s been 3,297 days since the last bear market ended on March 9, 2009. Ramsey points out that foreign stocks in the MSCI EAFE index have been lagging the U.S. market this year, and they now trade at 26% discount to the MSCI USA index based on “normalized” price/earnings ratios (which smooth out the volatility in earnings over multi-year periods). The EAFE traded at the same discount in May 2010—the start of an “epic phase of underperformance” compared with the U.S. market, he says in a recent blog post.
The cornerstone of asset allocation has been that bonds offer a buffer to stocks when they tumble. Two quant strategists took a closer look at where investors may want to seek cover: Pavilion Global Market’s quantitative macro analyst Antoine Naly says bonds have not always acted as a buffer for stock meltdowns. Going back to the 19 century, Naly says correlations between bond and equity returns sometimes turn positive—and for long periods of time too, when inflation rates were rising like in the 1970s. While Naly says we are a long ways off from those rates, there is evidence to suggest we are moving toward a more inflationary period, at least on a cyclical basis.
Abbott Laboratories (ABT) released its 4Q17 and fiscal 2017 earnings results on January 24, 2018. Abbott seems quite confident about its strong product pipeline and recent product launches. In 2017, Abbott Laboratories launched a number of innovative products and expanded across geographies and business segments.
Last week I highlighted the Top 10 Value Stocks In The S&P 500 noting that “value will have its day in the sun” in 2018. But what are the S&P 500’s most expensive stocks?
Large-cap and growth stocks continue to beat small-caps and value, even though everyone thought the tide would turn this year.
Growth stocks have surged this year in the ongoing post-election rally, but more recently, the value style and related exchange traded funds are beginning to pull ahead. Year-to-date, the iShares Russell ...
Stocks were mixed as Amgen and Celgene hurt biotechs, and ahead of ahead of Amazon and Alphabet's earnings after the close.
In 2017, Mylan (MYL) plans to submit BLAs to the FDA for the approval of biosimilars for trastuzumab, pegfilgrastim, bevacizumab, adalimumab, and insulin glargine.